54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 63

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

Background/Significance

Percutaneous thermal ablation has the potential to replace surgical treatment and improve the health-related quality of life of patients with small breast cancers, without jeopardizing current treatment effectiveness or safety. The objective of this study was to determine the efficacy rate in terms of complete ablation for the most promising techniques of thermal ablation: radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA) for patients with early-stage breast cancer to warrant a randomized, phase 3 trial comparing thermal ablation with surgery.

Materials and Methods

This was an investigator-initiated, randomized, phase 2 “pick a winner” study in postmenopausal patients with cT1N0 estrogen receptor–positive, HER2-negative breast cancer. Patients were randomly assigned to undergo RFA, MWA or CA, and underwent surgical resection 3 months after thermal ablation. The optimal technique should meet the minimum requirements of a complete ablation rate of at least 85%, a complication rate of ≤ 15%, and completion of the treatment without interruption due to pain or discomfort in at least 80% of patients. The primary outcome was proportion of patients with complete pathological response at pathology examination; secondary outcomes included ability to complete the thermal ablative procedure in an outpatient setting and the occurrence of adverse events (AEs).

Results

A total of 41 patients were included. Treatment in the RFA arm was terminated prematurely due to reaching a protocol defined stopping rule after 5 inclusions. Eighteen patients were treated with MWA and CA. All techniques were user-friendly and showed excellent feasibility in an outpatient setting. Complete ablation was reached in 72% (95% CI, 49%-88%) in the MWA arm and in 94% (95% CI, 74%-99%) in the CA arm. AEs occurred in 44% (95% CI, 25%-66%) and 0% (95% CI, 0%-18%) of patients in the MWA and CA arms, respectively.

Table 1. Primary and Secondary Outcomesa,b

Table 1. Primary and Secondary Outcomesa,b

Conclusion

Cryoablation was the only thermal ablative technique that met the minimum requirements and will therefore be selected for the phase 3 trial.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.